- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04886700
Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
14 novembre 2021 mis à jour par: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Single-arm, Open-label, Multicenter, Phase II Study for Evaluation of Efficacy and Safety of the SG001 Injection for Patients With PD-L1-positive Relapsed or Metastatic Uterine Cervical Cancer
This study is an open, single-arm, multicenter phase II study to investigate the efficacy and safety of SG001 for relapsed or metastatic uterine cervical cancer patients with PD-L1 positive (CPS≧1), and has failed at least first line platinum-based chemotherapy.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Description détaillée
Phase II: open, single-arm, multicenter.
Type d'étude
Interventionnel
Inscription (Anticipé)
104
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Beibei Zhai
- Numéro de téléphone: 0086-021-60673937
- E-mail: zhaibeibei@mail.ecspc.com
Lieux d'étude
-
-
-
Beijing, Chine, 100021
- Recrutement
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
-
Contact:
- Lingying Wu, Medical PhD
- Numéro de téléphone: 0086-010-67781331
- E-mail: wulingying@csco.org.cn
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Femelle
La description
Inclusion Criteria:
- 1. Age ≥ 18 on the day of signing informed consent and volunteered to participated in this study.
- 2. Histologically documented relapsed or metastatic uterine cervical cancer including squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma, a relevant pathological report must also be provided.
- 3. Relapsed or metastatic uterine cervical cancer patient who has failed at least first line platinum-based chemotherapy, which means having disease progression during or following at least first line platinum based chemotherapy or for which platinum based chemotherapy is not tolerated, having disease progression within 6 months of or during neoadjuvant or adjuvant treatment with platinum based chemotherapy can also be accepted.
- 4. Programmed Cell Death Ligand 1 (PD-L1) positive expression defined by Combined Positive Score (CPS) ≥1.
- 5. All the subjects should have at least one measurable lesion in CT or MRI test assessed by RECIST 1.1. A previously irradiated site lesion could only be counted as a target lesion if there was clear sign of progression since the irradiation.
- 6. If subjects have received anti-tumor therapies before, the toxicity severity must decrease to ≤ Grade1 evaluated by NCI-CTCAE 5.0, except for residual alopecia or fatigue.
- 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- 8. Has a predicted survival period ≥ 3 months assessed by investigators.
9. Demonstrate adequate organ function as defined below:
- Blood routine tests (No blood transfusions were performed, no hematopoietic stimulators were used, and no drugs were used to correct blood cell counts ): Absolute neutrophil count (ANC) ≥1.5×109/L; Platelets ≥75×109/L; Hemoglobin (HGB)≥9 g/dL;
- Serum biochemical indexs: Serum creatinine ≤1.5 X ULN or Creatinine clearance (CCr) ≥ 50mL/min; Serum total bilirubin (TBIL) ≤ 1.5 X upper limit of normal ULN (Subjects with Gilbert's syndrome can be up to 3 x ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X ULN or ≤5 X ULN for subjects with hepatocellular carcinoma and liver metastases;
- Coagulation function: Activated partial thromboplastin time (APPT) and International Normalized Ratio (INR)≤1.5 X ULN (No anticoagulants or other drugs affecting clotting function were used within 14 days prior to the first administration, except for subjects requiring long-term anticoagulant therapy).
- 10. Women of child-bearing potential (WOCBP) should be willing to use reliable contraceptive methods from signing the informed consent form to 6 months after last dose of investigational drug.
Exclusion Criteria:
- 1. History of allergic reactions attributed to any monoclonal antibody, and uncontrolled history of allergic asthma.
- 2. Patients with other types of malignant tumours that have progressed or require treatment within 5 years prior to the screening, but well-treated skin basal cell carcinoma, skin squamous cell carcinoma, or superficial bladder cancer, and having cured carcinoma in situ, e.g. breast carcinoma in situ, can be accepted.
- 3. Patients with any active autoimmune disease, but subjects with following diseases are allowed for further screening: subjects with well-controlled type I diabetes, well-controlled hypothyroidism with hormone replacement therapy, skin diseases (such as vitiligo, psoriasis, or hair loss) without systemic treatment, or who are not expected to relapse without external triggers.
- 4. History of primary immunodeficiency.
- 5. Patients with serious cardiovascular diseases, such as grade 2 or above heart failure based on the NYHA (New York Heart Association) Class guidelines, previous myocardial infarction within 3 months, poorly controlled arrhythmias or unstable angina pectoris, previous arterial or venous thrombosis events within 3 months (e.g. transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep vein thrombosis and pulmonary embolism).
- 6. Has history of Interstitial Lung Disease (Patients caused by radiotherapy are eligible), or non-infectious pneumonitis need for glucocorticoid therapy.
- 7. Have a history of active tuberculosis.
- 8. Subjects with untreated or treated but still symptomatic central nervous system metastases (except for residual signs or symptoms related to CNS treatment, those with stable or improved neurological symptoms at least 2 weeks prior to screening can be included).
- 9. Prior therapy with any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways including anti-PD-1, anti-PD-L1, anti CTLA-4, OX40 agonist, and anti-CD137, etc.
- 10. Immune-related adverse events of grade 3 or higher(NCI-CTCAE 5.0)after immune therapy.
- 11. Have received major surgery or radical radiotherapy within 28 days, or palliative radiotherapy within 14 days, or radiological agents (strontium, samarium, etc.) within 56 days prior to screening.
- 12. Have received systemic anti-tumour therapy 28 days before the first dose, including but not limited to chemotherapy, immunotherapy, macromolecular targeted therapy, and biological therapy (tumour vaccine, cytokines or growth factors controlling cancer); Patients who received small-molecule targeted and oral fluorouracil therapy within 14 days before the first dose.
- 13. Have received attenuated live vaccine within 28 days before the first dose or planned to receive during the study period.
- 14. Have received Chinese herbal medicine or Chinese patent medicine with anti-tumor activity within14 days prior to the first dose.
- 15. Any active infection requiring systemic treatment by intravenous infusion within 28 days prior to the first dose.
- 16. Have received systemic corticosteroids (at doses equivalent to or greater than 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to the first dose of study drug.
- 17. Have participated other clinical trials and received related investigated drugs within 28 days prior to the first dose of study drug (counted from the date of the last treatment in the previous clinical trial, patients participated in the overall survival follow-up of the previous clinical trial can be accepted).
- 18. Patients should be excluded if they have a positive test for human immunodeficiency virus antibody (HIV-Ab) or treponema pallidum antibody (TP-Ab). Patients with positive Hepatitis B virus surface antigen (HBsAg) and/or hepatitis B virus core antibody (HBcAb) as well quantitative HBV-DNA above upper limit of normal value, and patients with positive hepatitis C virus antibody (HCV-Ab) as well quantitative HCV-RNA above upper limit of normal value, should also be excluded.
- 19. Pregnant or lactating women; Or the blood pregnancy test of women at child-bearing age is positive during screening.
- 20. Other conditions that may increase the risk of drug use in the study, or interfere with the interpretation of the study results, or affect the compliance of the study, etc.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: SG001
Recombinant Human Anti-PD-1 Monoclonal Antibody
|
Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Objective response rate (ORR) by RECIST1.1 in relapsed or metastatic uterine cervical cancer evaluated by IRC (Independent Review Committee), confirmation of CR and PR is required in at least 4 weeks after initial documentation.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
ORR (objective response rate) evaluated by investigators.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
DOR (duration of response) evaluated by IRC.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
DCR (disease control rate) evaluated by IRC.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
PFS (free-progression survival) evaluated by IRC.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
OS (overall survival) evaluated by IRC.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
TTR (time to response) evaluated by IRC.
Délai: From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
To investigate the efficacy of SG001 in relapsed or metastatic uterine cervical cancer.
|
From first dose to the first documented progression of disease, subject withdrawal, lose to follow-up, death, initiating a subsequent cancer therapy, or study completion or termination, whichever occurs earliest, assessed up to 24 months.
|
Amount, severity, and duration of TEAEs (treatment emergent adverse event) evaluated by NCI-CTCAE V5.0.
Délai: From the date of signing Informed Consent Form (ICF) up to 28 days following the last dose of study drug, immune related adverse events will be recorded until 90 days after the last dose.
|
To investigate the safety and tolerance profile of SG001 in patients with relapsed or metastatic uterine cervical cancer.
|
From the date of signing Informed Consent Form (ICF) up to 28 days following the last dose of study drug, immune related adverse events will be recorded until 90 days after the last dose.
|
Population pharmacokinetic parameter IIV (interindividual variability).
Délai: At the end of cycle 7 (every cycle is 14 days).
|
The pharmacokinetic profile of SG001.
|
At the end of cycle 7 (every cycle is 14 days).
|
Population pharmacokinetic parameter exposure-response relationship.
Délai: At the end of cycle 7 (every cycle is 14 days).
|
The pharmacokinetic profile of SG001.
|
At the end of cycle 7 (every cycle is 14 days).
|
Immunogenicity of SG001, such as anti-drug antibody and neutralizing antibody.
Délai: From the first dose of study drug to the end of treatment visit, up to 24 months.
|
To investigate the immune profile of SG001.
|
From the first dose of study drug to the end of treatment visit, up to 24 months.
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Les enquêteurs
- Chercheur principal: Lingying Wu, Medical PhD, Chinese Academy of Medical Sciences and Peking Union Medical College
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
31 juillet 2021
Achèvement primaire (Anticipé)
31 décembre 2022
Achèvement de l'étude (Anticipé)
31 décembre 2023
Dates d'inscription aux études
Première soumission
26 avril 2021
Première soumission répondant aux critères de contrôle qualité
12 mai 2021
Première publication (Réel)
14 mai 2021
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
22 novembre 2021
Dernière mise à jour soumise répondant aux critères de contrôle qualité
14 novembre 2021
Dernière vérification
1 mai 2021
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SYSA1802-CSP-004
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du col de l'utérus
-
Imperial College Healthcare NHS TrustImperial College London; The Wellington Hospital, LondonComplété
-
Duke UniversityNational Cancer Institute (NCI); Jacobi Medical CenterComplété
-
Michigan State UniversityAmerican Osteopathic AssociationComplété
-
Duke UniversityUniversity of ArkansasComplété
-
New York Institute of TechnologyComplété
-
Michigan State UniversityComplété
-
NuVasiveActif, ne recrute pasTrouble discal dégénératif cervicalÉtats-Unis
-
Goethe UniversityComplétéCinématique | Fiabilité | CervicalAllemagne
-
Xin Jiang, MDInconnueBloc du plexus cervical superficielChine
-
National Cancer Institute (NCI)ComplétéPoumon | Sein | Ovaire | Cervical | RénalÉtats-Unis
Essais cliniques sur SG001
-
Shanghai Runshi Pharmaceutical Technology Co., LtdPas encore de recrutement
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecrutementLymphome | Cancer du col de l'utérus | Mésothéliome malin | Tumeurs solides avancées | Cancer du poumon non à petites cellulesChine
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Pas encore de recrutement
-
Shanghai JMT-Bio Inc.Pas encore de recrutementCancer colorectal métastatique (mCRC)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Recrutement
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Pas encore de recrutementCarcinome épidermoïde de l'œsophage non résécable localement avancéChine
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Pas encore de recrutementCancer du col de l'utérus récurrent ou métastatique avec PD-L1 positif (CPS≥1)
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Pas encore de recrutementCancer de la trompe de Fallope | Cancer épithélial de l'ovaire | Cancer péritonéal
-
CSPC Ouyi Pharmaceutical Co., Ltd.Pas encore de recrutementCholangiocarcinome intrahépatique | Carcinome de la vésicule biliaire | Cancer avancé des voies biliaires | Cholangiocarcinome extrahépatiqueChine